Enlivex Therapeutics Ltd. financial data

Symbol
ENLV on Nasdaq
Location
Tel Aviv
Fiscal year end
31 December
Latest financial report
6-K - Q2 2025 - 29 Aug 2025

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 23,650,989 shares 27%
Common Stock, Shares, Outstanding 23,858,301 shares 14%
Common Stock, Value, Issued $2,708,000 USD 14%
Weighted Average Number of Shares Outstanding, Basic 23,855,663 shares 22%
Weighted Average Number of Shares Outstanding, Diluted 23,855,663 shares 22%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $2,141,000 USD 7.1%
General and Administrative Expense $937,000 USD -5.1%
Operating Income (Loss) $3,078,000 USD -3.1%
Nonoperating Income (Expense) $1,210,000 USD
Net Income (Loss) Attributable to Parent $1,868,000 USD 40%
Earnings Per Share, Basic -0.08 USD/shares 50%
Earnings Per Share, Diluted -0.08 USD/shares 50%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $1,892,000 USD -50%
Marketable Securities, Current $6,000 USD -97%
Assets, Current $21,324,000 USD -25%
Property, Plant and Equipment, Net $490,000 USD -58%
Operating Lease, Right-of-Use Asset $433,000 USD -50%
Other Assets, Noncurrent $784,000 USD -39%
Assets $22,598,000 USD -29%
Accounts Payable, Current $303,000 USD
Employee-related Liabilities, Current $347,000 USD 11%
Accrued Liabilities, Current $2,786,000 USD
Liabilities, Current $3,328,000 USD 17%
Operating Lease, Liability, Noncurrent $216,000 USD -57%
Other Liabilities, Noncurrent $216,000 USD -57%
Liabilities $3,544,000 USD 6.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,101,000 USD 0%
Retained Earnings (Accumulated Deficit) $132,427,000 USD -11%
Stockholders' Equity Attributable to Parent $19,054,000 USD -33%
Liabilities and Equity $22,598,000 USD -29%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 45,000,000 shares 0%
Common Stock, Shares, Issued 23,858,301 shares 14%
Common Stock, Par or Stated Value Per Share 0.4 ILS/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2,348,000 USD -44%
Deferred Tax Assets, Valuation Allowance $37,294,000 USD 11%
Deferred Tax Assets, Gross $37,294,000 USD 11%
Operating Lease, Liability $480,000 USD -43%
Depreciation $85,000 USD -47%
Lessee, Operating Lease, Liability, to be Paid $561,000 USD -41%
Property, Plant and Equipment, Gross $3,650,000 USD -13%
Operating Lease, Liability, Current $264,000 USD -21%
Lessee, Operating Lease, Liability, to be Paid, Year Two $147,000 USD -24%
Lessee, Operating Lease, Liability, to be Paid, Year One $170,000 USD -52%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 29%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $81,000 USD -26%
Lessee, Operating Lease, Liability, to be Paid, Year Three $99,000 USD -15%
Deferred Tax Assets, Operating Loss Carryforwards $31,520,000 USD 17%
Lessee, Operating Lease, Liability, to be Paid, Year Four $88,000 USD -27%
Additional Paid in Capital $147,672,000 USD
Share-based Payment Arrangement, Expense $295,000 USD -24%